| Literature DB >> 30181528 |
Gregory Nicolas1, Haydar Nasser2, Juliano Haddad3, Elie Zaghrini4, Karim Daher1, Amal Assef Nasser5, Christian Saliba1, Nour Gharios6, Raja Wakim7.
Abstract
BACKGROUND Duodenal and ampullary carcinoids are very rare tumors accounting respectively for 2% and 0.03% of all carcinoid tumors. Clinical findings vary according to the location of the tumor within the periampullary region; with epigastric pain being the most common presenting symptom in duodenal carcinoids and jaundice the most common clinical finding in ampullary carcinoids. Treatment options include pancreaticoduodenectomy, local excision, and endoscopic excision. CASE REPORT In this case report, we present a 60-year-old male who presented with a one-week history of intractable epigastric pain. He was diagnosed with duodenal periampullary carcinoid tumor and treated with local excision. CONCLUSIONS Although duodenal and ampullary carcinoid tumors may have different clinical presentations, as well as histochemistry characteristics and metastatic potential, they appear to benefit from the same surgical treatment.Entities:
Mesh:
Year: 2018 PMID: 30181528 PMCID: PMC6135042 DOI: 10.12659/AJCR.908205
Source DB: PubMed Journal: Am J Case Rep ISSN: 1941-5923
Laboratory values upon presentation showing disturbances in pancreatic and hepatic enzymes.
| White blood cells | 9500/mm3 |
| Hematocrit | 41% |
| SGOT | 114 U/L |
| SGPT | 217 U/L |
| Alkaline phosphatase | 345 UI/L |
| Total bilirubin | 1.11 mg/dL |
| Direct bilirubin | 0.2 mg/dL |
| Amylase | 167 U/L |
| Lipase | 648 U/L |
| C-reactive protein | 66 mg/L |
Figure 1.Computed tomography showing a hypodense polypoid duodenal mass about 2 cm in diameter near the ampulla (arrows) with distended gallbladder (arrowhead).
Figure 2.Upper gastrointestinal endoscopy showing a pedunculated ulcerated 5 cm duodenal mass near the papilla, with bleeding upon contact.
Figure 3.An endoscopic retrograde cholangiopancreatography showing an irregular mass with contrast pooling around it.
Figure 4.Follow-up octreotide scintigraphy performed 3 months after the operation with no uptake of radioactive material.